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Abstract
Objective: Comparing scoring with RMI3 and RMI4 in 
establishing the diagnosis of adnexal tumour in RSUD Dr. 
Saiful Anwar Malang.
Methods: Prospective cohort study with samples of all 
patients suspected of having an adnexal tumour diagnosed 
in gynecology policlinic using gynecological oncology 
policlinic medical records at RSUD Dr. Saiful Anwar in the 
form of age, demographics, menopause status, Ca125, 
ultrasound results.
Results: Between the RMI3 results and the results of 
histopathology, a contingency coeffi cient of 0.596 was 
obtained with a p-value of 0.000015 (p <0.05), with a PPV 
of 83%, an NPV of 91%. Between the RMI4 results and the 
histopathology results, a contingency coeffi cient of 0.657 
with a p-value of 0.0000004 (p <0.05) was obtained, with a 
PPV of 92%, NPV of 95%. On the ROC curve, the area of the 
predicted results using the RMI4 score is higher than the 
RMI3 score.
Conclusions: Using the RMI4 score results in more accurate 
predictions than the RMI3 score in detecting adnexal tumour 
malignancies.
Keywords: adnexal tumours, diagnostic tests, ovarian 
tumours, risk of malignancy index, ultrasound.
Abstrak
Tujuan: Membandingkan Skoring RMI3 dan RMI4 dalam 
menegakkan diagnosis tumor adneksa di RSUD dr. Saiful 
Anwar Malang.
Metode: penelitian kohort prospective dengan sampel 
semua pasien yang dicurigai menderita tumor adneksa 
yang didiagnosis di poli Ginekologi menggunakan data 
rekam medis poli Ginekologi Onkologi RSUD dr. Saiful 
Anwar berupa usia, demografi , status menopause, Ca125, 
hasil USG.
Hasil: Antara hasil RMI3 dengan hasil hispatologi, 
didapatkan koefi sien kontingensi sebesar 0,596 dengan 
p-value ,.000015 (p<0,05), dengan PPV 83%, NPV 91%. 
Antara hasil RMI4 dengan hasil histopatologi, didapatkan 
koefi sien kontingensi sebesar 0,657 dengan p-value 
0.0000004 (p<0,05), dengan PPV 92%, NPV 95%. Pada kurva 
ROC, luas area hasil prediksi dengan menggunakan skor 
RMI4 lebih tinggi daripada skor RMI3.
Kesimpulan: Menggunakan skor RMI4 menghasilkan 
prediksi yang lebih tepat daripada skor RMI3 dalam 
mendeteksi keganasan tumor adneksa.
Kata kunci: risk of malignancy index, tumor adneksa, tumor 
ovarium, uji diagnostik, USG.
INTRODUCTION
Ovarian tumor is a growth of tissue in the 
form of a lump originating from the ovary, which 
can be either solid or liquid / cystic. Like other 
tumours, ovarian tumours can be malignant or 
can be benign. Ovarian cancer ranks second 
among all gynecological cancers in developing 
countries, and is ranked as the fi fth leading 
cause of mortality due to malignancy in women 
and is the most common cause of death among 
gynecological malignant tumours. In the United 
States, there were approximately 21.290 new 
cases and 14.180 deaths in 2015 as a result of 
ovarian cancer. Ovarian cancer accounts for 5% 
of all cancers among women1.
The ovary is located inside the abdominal 
cavity so there is no easy access to obtain 
tissue samples for malignancy. Therefore, an 
examination formula is needed for the basis of 
ovarian malignancy suspicion. Examination of 
tumour antigen 125 tumour markers (CA-125), 
ultrasonography, postmenopausal age, and parity 
can increase suspicion of ovarian malignancy2.
A number of examination formulas have 
been developed in various countries carried 
out in order to establish a suspicious diagnosis 
of preoperative ovarian cancer. There are 
many formulas for suspecting pre-malignant 
malignancy for ovaries such as the Risk of Ovarian 
Malignancy Algorithm (ROMA), Risk of Ovarian 
Cancer Algorithm (ROCA), Gatot Purwoto Score 
and many other examination formulas, made to 
be implemented in various inspection sites based 
on the conditions of the facilities available3.
The Risk of Malignancy Index (RMI), known as 
RMI 1, in its development has undergone many 
validations and comparisons of its sensitivity and 
specifi city, with different research designs and 
results that are not always the same. Until now 
the International Federation of Gynecology and 
Obstetrics (FIGO) is still guided by RMI-1 which 
was fi rst formulated in 19904.
A more accurate scoring system is needed 
in predicting preoperative malignancies to 
reduce morbidity and mortality due to ovarian 
malignancies. Risk of Malignancy Index 3 (RMI3) 
is the result of U x M x CA 125 calculations. 
Ultrasonography includes multilocularity, solid 
areas, bilaterality, ascites, and intraabdominal 
metastases resulting in one point each. A total 
of 2 or more points are recalculated to U = 3, 
less than 2 points to U = 1. Menopausal status is 
defi ned as more than 1 year of amenorrhea, or 
age 50 years or more among women who have 
had previous hysterectomy, and postmenopausal 
status M score = 3; premenopausal status score 
M = 1. Serum CA 125 (U / mL) is entered directly 
into the equation where a cut-off value of 200 
indicates discrimination between benign and 
malignant adnexal masses. In the study l RMI3 
with a cut-off rate of 200 has an accuracy of 86%5.
Risk of Malignancy Index 4 (RMI4) is the result 
of the calculation of U x M x S x CA 125. The total 
score of USG 0 or 1 is recalculated to U = 1, and 
the score 2 becomes U = 4. Premenopausal status 
score M = 1 and status score postmenopausal M 
= 4. Tumour size was obtained from ultrasound. 
Tumour size (largest single diameter) <7 cm 
was recalculated to S = 1, and ≥7 cm to S = 2, 
Serum CA 125 (U / mL) was applied directly to 
calculations where a cut-off value of 450 showed 
discrimination between benign adnexal masses 
and ferocious. In the study RMI4 with a cut-off 
rate of 450 has an accuracy of 90.4%5.
METHODS
This study uses a prospective cohort study 
design that compares diagnostic tests using 
Risk of Malignancy Index 3 (RMI3) and Risk of 
Malignancy Index 4 (RMI4) in adnexal tumour 
patients. This research was conducted in October 
2018 - April 2019, with samples of all patients 
suspected of having an adnexal tumour diagnosed 
in gynecology policlinic using gynecological 
oncology policlinic medical records at RSUD Dr. 
Saiful Anwar in the form of age, demographics, 
menopause status, Ca125, ultrasound results. 
The exclusion criteria are patients with adnexal 
masses not from the ovary, patients suffering 
from other malignancies, patients with infected 
adnexal masses, and pregnant patient with 
adnexal tumour.
In this study, the data analysis technique was 
carried out with several test methods. To test the 
numerical variables, the T-test was used, while 
with the categorical variables, the Chi-square test 
was used. To test the comparison of the accuracy 
of predictions between scoring RMI3 and RMI4 
we used the contingency coeffi cient test and 
the ROC curve to determine the cut-off value of 
RMI3 and RMI4.
RESULTS
Based on the inclusion and exclusion criteria, 
there were 22 samples in the benign category 
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and 12 samples in the malignant category. The 
following are the characteristics of the research 
sample that have been studied: the average age 
of 22 patients in the benign category was 42.1 ± 
13.6 years and in 12 patients the malignant group 
was 54.2 ± 10.3 years. Using an independent 
t-test, a p-value of 0.012 (p <0.05) indicates that 
there is a statistically signifi cant age difference.
The data in table 1 also shows that 8 
nulliparous patients (23.5%) experienced ovarian 
malignancy. By using the Chi-Square test, the 
p-value was 0.012 (p <0.05) which explained that 
there was a signifi cant difference between parity 
characteristics and ovarian malignancy.
The benign adnexal tumour patient group has 
not experienced menopause in 17 (50%) patients, 
while in the malignant adnexal tumour group 
mostly have experienced menopause, which is 
7 (20.6%) patients. Using the Chi-Square test, a 
p-value of 0.038 (p <0.05) was obtained which 
explained that there were differences in the 
characteristics of menopause between the two 
groups of patients.
Genetic factors analyzed in this study were 
family history of the gynecologic tumour. Based 
on genetic factors (Table 1), a p-value of 0.001 
was obtained (p <0.05). From this study it was 
shown that there were signifi cant differences in 
genetic factors between benign adnexal tumour 
patients and malignant category.
Table 1 shows that in both groups of patients, 
both benign adnexal tumour patients and 
malignant categories, most had junior high 
school education: 11 (32.4%) and 6 (17.6%) 
patients respectively. Using the Chi-Square 
test, a p-value of 0.493 (p> 0.05) was obtained 
which explained that there were no differences 
in educational characteristics between the two 
groups of patients.
Based on the tumour type, it was shown table 
2 that in patients in the malignant category, the 
most common type of serous tumour cell types 
was found in 6 (17.6%) patients. Whereas in the 
benign category, the most common type was 
mucinous cystadenoma in 6 (17.6%) patients.
Table 1. Study Sample Characteristics
Characteristics P-value
Category
Age (mean ±SD)
Education
Elementary school
Junior high school
Senior high school
University
Parity
Nulliparous
Primi / Multiparous
Menarche (y.o)
≤ 11
> 11
Menopause
Not Yet
Already
Family history of Gynecologic 
cancer (Genetic Factor)
Yes
No
Benign (n = 22)
42.1 ± 13.6
0 (0)
11 (32.4)
10 (29.4)
1 (2.9)
5 (14.7)
17 (50)
0 (0)
22 (64.7)
17 (50)
5 (14.7)
4 (11.8)
18 (52.9)
Malignant (n=12)
54.2 ± 10.3
1 (2.9)
6 (17.6)
5 (14.7)
0 (0)
8 (23.5)
4 (11.8)
2 (5.9)
10 (29.4)
5 (14.7)
7 (20.6)
9 (26.5)
3 (8.8)
0.012
0.493
0.012
0.048
0.038
0.001
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Table 2. Tumour Type Characteristics
Mucinous Carcinoma Ovarium
Endometrioid Adenocarcinoma
High-Grade Serous Ovary Carcinoma
Adenocarcinoma
Serous Cystadenoma Ovary
Mucinous Cystadenoma Ovary
Hemorrhagic Cyst
Dermoid Cyst
Endometriosis Cyst
Mature Teratoma
Infected Cyst
Fibroma Ovary
Tumour Type Benign (%) Malignant (%)
3 (8.8)
6 (17.6)
3 (8.8)
3 (8.8)
3 (8.8)
1 (2.9)
2 (5.9)
1 (2.9)
3 (8.8)
1 (2.9)
6 (17.6)
2 (5.9)
Figure 2. Plot of Sensitivity and Specifi city of RMI 3 Score.
The RMI 3 plot sensitivity and specifi city curve 
show the intersection point of the curve located 
at a score of 183.8. Based on this study, the 
sensitivity is 0.917 and the specifi city is 0.909.
As explained in Figure 2, it is shown that there 
is an intersection of sensitivity and specifi city 
values. This intersection shows the optimum 
value that can be used as a cut-off value or 
limitation in determining the level of malignancy 
of adnexa tumours. The cut point is obtained 
from the combination of the highest sensitivity 
and specifi city values. It is shown that the 
highest combination of sensitivity and specifi city 
values lies at point 183.8 where at that point a 
sensitivity value of 0.917 and specifi city of 0.909 
Table 3. Comparison of Contingency Coeffi cient between RMI3 and RMI4
RMI3
Malignant
Benign
RMI4
Malignant
Benign
10 (29.4)
2 (5.9)
11 (32.4)
1 (2.9)
2 (5.9)
20 (58.8)
1 (2.9)
21 (61.8)
0.596
0.657
0.000015
0.000004
83
92
91
95
Score Histopathology
Malignant Benign
PPV
(%)
NPV
(%)
Contingency 
Coeffi cient
P-value
Comparison of the accuracy of RMI3 with 
RMI4 in predicting adnexal tumour malignancy 
can be done using contingency coeffi cients, 
ie comparing the results of RMI3 and RMI4 
calculations with the results of histopathological 
examination. From this study, a contingency 
coeffi cient of 0.596 was obtained with a p-value 
of 0.000015 (p <0.05. It was shown that there 
was a signifi cant relationship between the results 
of RMI3 with the results of histopathology. The 
positive predictive value (PPV) was 83% and 
negative predictive value was 91%. From 22 
patients with benign adnexal tumour category 
based on histopathology, there were 2 (5.9%) 
patients who predicted malignant tumours. While 
from 12 patients with malignant adnexal tumour 
category based on histopathology, there were 
The contingency coeffi cient on the RMI3 
score is 0.596 and the RMI4 score is 0.657. The 
contingency coeffi cient of the RMI4 score is 
higher than the RMI3 score. This proves that the 
results of the assessment using the RMI4 score 
produce more accurate predictions than the RMI3 
score in detecting adnexal tumour malignancies. 
The accuracy of the RMI score of 3 with the RMI4 
score for predicting adnexal tumour malignancy 
can be measured using a Receiver Operating 
Characteristic (ROC) curve.
Figure 1. ROC Curves of RMI3 Score and RMI4 Score. 
2 (5.9%) patients who were predicted as benign 
tumours.
In the contingency coeffi cient test of the 
relationship between the results of RMI4 with 
the results of histopathology, the contingency 
coeffi cient was 0.657 with a p-value of 0.0000004 
(p <0.05). From this test it was shown that there 
was a signifi cant relationship between the results 
of RMI4 with the results of histopathology. The 
positive predictive value (PPV) was 92% and 
negative predictive value was 95%. From 22 
patients with benign adnexal tumour category 
based on histopathology, there were 1 (2.9%) 
patients predicted by malignant tumours, while 
from 12 patients with malignant adnexal tumour 
categories based on histopathology, 1 patient 
was predicted as a benign tumour.
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Figure 3. Plot of Sensitivity and Specifi city of RMI 4 Score.
are shown. Thus, the cut-off value of the RMI3 
score to determine the level of adnexal tumour 
malignancy was 183.8.
(49 years)7. The epidemiological study of meta-
analysis of 125 articles published in 1925-2018 
stated that the average age of ovarian cancer 
was detected at 50-79 years old. Detection at 
an advanced age shows a more severe disease 
severity and a lower survival rate8.
Epidemiological studies show an inconsistent 
association between the age of menarche and 
the risk of ovarian cancer. A total of 10 (29.4%) 
patients who experienced menarche at the age 
above 11 years experienced ovarian malignancy, 
although it was not statistically signifi cant (p = 
0.048). A meta-analysis study revealed that the 
age of menarche has an inverse relationship 
with ovarian cancer risk (RR = 0.85; 95% 
confi dence interval (95% CI) 0.75–0.97). The 
inverse relationship between menarche age and 
risk of ovarian cancer can be partly explained 
by the hypothesis of "incessant ovulation" 
and some hormonal changes in childhood and 
adolescence. Ovarian carcinogenesis involves 
several mechanical sequels to ovulation, such as 
trauma or stimulation of mitosis to the ovarian 
epithelium. Similar to pregnancy and the use of 
oral contraceptives, the age of menarche which 
may then reduce the risk of ovarian cancer is 
associated with a reduced number of ovulation 
for a woman's lifetime. On the other hand, early 
menarche is associated with the onset of a faster 
ovulation cycle and a tendency to maintain higher 
levels of luteal phase estradiol and progesterone. 
Progestins can increase apoptosis in the ovarian 
epithelium. Women who experience menarche at 
an older age may experience low levels of extra 
estrogen (or other hormones) stimulation of their 
ovarian epithelium without the apoptotic effect 
of progesterone. Meanwhile, androgens, which 
are also relatively common in girls with older 
menarcheal ages, have been shown to stimulate 
DNA synthesis and reduce cell death in ovarian 
cell culture lines9.
Some control cases show that multiparous 
women have a 30-60% lower risk of ovarian cancer. 
Increased parity is associated with a reduced risk 
of ovarian malignancy8. This study revealed that 
in patients with adnexal tumours who came to 
RSSA in October 2018 - April 2019, the highest 
proportion diagnosed with ovarian cancer was 
in the nullipara group of 8 patients (23.5%). 
This study showed that there was a signifi cant 
difference between parity and the incidence 
of malignancy in adnexal tumours (p = 0.012). 
Pregnancy decreases the risk of ovarian tumour 
malignancy by as much as 19%. The effect of 
The RMI 4 plot sensitivity and specifi city curve 
show the intersection point of the curve located 
at a score of 463.54. Based on this study, the 
sensitivity of RMI 4 is 0.954 and the sensitivity of 
RMI 4 is 463.54.
Based on Figure 3, it is shown that there is an 
intersection of sensitivity and specifi city values. 
It is shown that the highest combination of 
sensitivity and specifi city values is at point 463.54 
where at that point the sensitivity value is 0.917 
and specifi city is 0.954. Thus, the cut-off value of 
the RMI4 score to determine the level of adnexal 
tumour malignancy was 463.54.
DISCUSSION
Ovarian Cancer Risk Factors
This study conducted an evaluation in patients 
with a diagnosis of adnexal tumour in RSUD dr. 
Saiful Anwar in October 2018 - April 2019, received 
a total of 34 samples with a distribution of 22 
(68.75%) benign cases and 12 (35.7%) malignant 
cases. The results obtained in this study are 
similar to multicenter cohort studies conducted 
in the United States where the oncology centre 
shows a higher malignancy rate that is between 
22-66% compared to other centres (0-30%)6.
The mean age of the sample involved in this 
study in benign and malignant cases was 42.1 
± 13.6 years and 54.2 ± 10.3 years, respectively. 
The mean age of malignant cases was found 
to be higher than benign cases and statistically 
showed signifi cant differences (p = 0.012). The 
average age of benign ovarian tumours in this 
study is older than the research conducted in 
India, which is between 20-40 years. The mean 
age of malignancy presentation in this study is 
consistent with studies in India (48 years) and Iran 
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pregnancy on reducing the risk of ovarian cancer 
is consistent with the hypothesis that anovulation 
reduces the risk of ovarian cancer in women by 
reducing the risk of mutation of epithelial cells 
at risk of becoming malignant. Pregnancy plays 
a greater role in reducing the risk of ovarian 
cancer than the anovulation caused by the use 
of contraception. Hormonal changes that occur 
in pregnancy are thought to induce apoptosis of 
premalignant cells.10
Tumour malignancy compared to women 
who do not use or only use it in the short term10. 
This study did not show a signifi cant relationship 
between the effect of hormones on adnexal 
tumour malignancy. This can be caused by the 
distribution of contraceptive users and fertility 
drugs in small samples.
RMI3 and RMI4 as Diagnostic Test
In the study group stated that there were no 
statistically signifi cant differences in identifying 
different risk index for malignancies between RMI 
1, RMI 2, RMI 3, and RMI 4, but RMI 2 was a better 
indicator in distinguishing benign and malignant 
diseases. In 2001 compares RMI 1, RMI 2, and RMI 
3 with each other and also confi rms that there 
are no statistical differences between the three 
indices in benign malignancy discrimination. In 
their study, using a cut-off of 120, found that RMI 
1 had a sensitivity of 72% and specifi city of 87%; 
RMI 2 has a sensitivity of 76% and a specifi city 
of 81%; RMI 3 has a sensitivity of 74% and a 
specifi city of 84%.
In a study of 34 patients with adnexal 
tumour in RSUD dr. Saiful Anwar Malang, the 
obtained accuracy of RMI3 was (P <0.05) at a 
cut-off level of 183.8, with sensitivity, specifi city, 
positive predictive value, negative predictive 
value and accuracy of 91%, 90%, 83%, and 91%, 
respectively, while the accuracy of RMI4 was (p 
<0.05) at the cut-off level 463 with the value of 
sensitivity, specifi city, positive predictive value, 
negative predictive value and accuracy of 91%, 
95%, 92%, and 95%, respectively. These results 
do not differ greatly in the study of Yamamoto 
et al. who developed RMI using tumour size 
and called it RMI 4. Their study confi rmed that, 
at a cut-off rate of 450, the accuracy of RMI 4 
was better than RMI 1 (p = 0.0013), RMI 2 (p 
= 0.0009) and RMI 3 (p = 0.0013) with a cut-
off rate of 200. They observed that at a cut-off 
level of 450, the sensitivity, specifi city, positive 
predictive value, negative predictive value and 
accuracy were 86.8%, 91.0%, 63.5%, 97,5% and 
90.4% respectively. In this study, the sensitivity, 
specifi city, positive predictive value, negative 
predictive value and accuracy were 85%, 87%, 
60%, 95%, and 86%, respectively, which were 
comparable to the results.
A study of 548 patients, with a mean age 
of 52 for those with benign lesions and 62 for 
those with malignant masses. This study involved 
415 benign masses (76%), 80 malignant masses 
(24%), and 53 boundary malignancies (10%). The 
most common benign and malignant masses are 
cystadenoma and serous cystadenocarcinoma. 
They calculated the RMI with a cut-off point of 200, 
where sensitivity, specifi city, PPV, and NPV were 
81%, 85%, 48%, and 96%, respectively4. Additional 
research was performed on 152 patients with 
pelvic mass (mean age for benign masses is 45 
and for malignant ones, it is 49). Of this mass, 
38.8% (n = 62) was proven to be benign (the 
most common was cystadenoma) and 61.2% (n 
= 93) proved to be malignant (the most common 
was serous cystadenocarcinoma)11. Three RMI 
is checked without suffi cient differences in the 
calculated parameters and at all RMI the best cut-
off point is at 200. A study of 100 patients with 
pelvic mass and the best cut-off point for RMI 
was 200, where sensitivity, specifi city, PPV, and 
NPV were 90%, 89%, 96%, and 78%, respectively.
The result of this study shows the ROC curve 
presents the predicted results of the RMI3 score 
in predicting the level of malignancy of adnexal 
tumours, with p-value (p <0.05) and an area of 
0.962 with 95% CI of 0.907 - 1.017. A p-value of less 
than 0.05 indicates that the RMI3 score is good 
for use in predicting the level of malignancy of 
adnexal tumours. While the results of prediction 
RMI4 scores in predicting the level of adnexal 
tumour malignancy, we obtained p-value (p 
<0.05) with an area of 0.973 and 95% CI of 0.929 
- 1.027. A p-value of less than 0.05 indicates that 
the RMI4 score is better for use in predicting the 
level of adnexal tumour malignancy.
In our study, the contingency coeffi cient on 
the RMI3 score was 0.596 and the RMI4 score was 
0.657. The contingency coeffi cient of the RMI4 
score is higher than the RMI3 score. This proves 
that the results of the assessment using the RMI4 
score produce more accurate predictions than 
the RMI3 score in detecting adnexal tumour 
malignancies.
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CONCLUSION
The results of this study indicate that RMI4 is 
better when compared with RMI 3 in predicting 
the level of adnexal tumour malignancy. This 
is consistent with the results of several studies 
related to pelvic tumours where RMI4 is more 
sensitive and specifi c in predicting tumours in the 
pelvis, especially adnexal tumours. The RMI 4 is 
better than RMI3 because there is a tumour size 
as an indicator. This is in line with the TMN system 
where the TMN system is used to determine the 
stage in the tumour.
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